dc.contributor.author | Valan, Christine Damgaard | |
dc.contributor.author | Slagsvold, Jens Erik | |
dc.contributor.author | Halvorsen, Tarje Onsøien | |
dc.contributor.author | Herje, Martin | |
dc.contributor.author | Bremnes, Roy M. | |
dc.contributor.author | Brunsvig, Paal Fr. | |
dc.contributor.author | Brustugun, Odd Terje | |
dc.contributor.author | Fløtten, Øystein | |
dc.contributor.author | Levin, Nina | |
dc.contributor.author | Sundstrøm, Stein Harald | |
dc.contributor.author | Grønberg, Bjørn Henning | |
dc.date.accessioned | 2018-05-07T07:54:29Z | |
dc.date.available | 2018-05-07T07:54:29Z | |
dc.date.created | 2018-01-18T00:57:32Z | |
dc.date.issued | 2018 | |
dc.identifier.issn | 0250-7005 | |
dc.identifier.uri | http://hdl.handle.net/11250/2497271 | |
dc.description.abstract | Background/Aim: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules of thoracic radiotherapy (TRT) in LD SCLC to investigate whether there were survival differences between N3 subcategories (n=144). Patients and Methods: Patients with a baseline CT scan available were analysed. Patients received four courses of cisplatin/etoposide and TRT of 45 Gy/30 fractions (twice daily) or 42 Gy/15 fractions (once daily). Results: Median overall survival (OS) was 23.3 months in the whole cohort. N3-patients (n=37) had shorter survival than those with N0-2 (16.7 vs. 33.0 months; p<0.001). There were no significant OS-differences between the N3 subcategories, but patients with metastases to two or more N3 regions had shorter survival than other N3 patients (13.4 vs. 19.9 months; p=0.011). Conclusion: There were no survival differences between the N3 subcategories, suggesting that all N3 disease should be considered as LD. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | International Institute of Anticancer Research (IIAR) | nb_NO |
dc.title | Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | acceptedVersion | nb_NO |
dc.source.pagenumber | 871-876 | nb_NO |
dc.source.volume | 38 | nb_NO |
dc.source.journal | Anticancer Research | nb_NO |
dc.source.issue | 2 | nb_NO |
dc.identifier.doi | 10.21873/anticanres.12296 | |
dc.identifier.cristin | 1545898 | |
dc.description.localcode | This article will not be available due to copyright restrictions (c) 2017 by International Institute of Anticancer Research (IIAR) | nb_NO |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Institutt for klinisk og molekylær medisin | |
cristin.ispublished | false | |
cristin.fulltext | postprint | |
cristin.qualitycode | 1 | |